- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00322699
Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patient Evaluation and Treatment:
- Patients will sign an IRB-approved informed consent form
Initial patient assessments will include:
- eligibility
- History and physical.
- clinical profile
- upper urinary tract imaging (if clinically indicated)
- urinary symptoms assessment
WBPDT Treatment:
- Porfimer Sodium (Photofrin) 1.5 mg/kg iv followed 2 days later by whole bladder laser light at 630 nm with target light doses of 1200 Joules (+/-100Joules)
- Patients will undergo three sequential WBPDT treatments
- Treatments will occur at least three months apart
All WBPDT treatments will occur within 12 months
Decisions to administer a second or third WBPDT will be based upon urological and medical assessment of the individual patient and not necessarily dependent upon Dose Limiting Toxicities (DLT) or early stopping endpoints (although such information may be taken into account in the individual patient assessment). Patients experiencing DLT may continue WBPDT at the investigator's discretion at the same or reduced doses of Porfimer Sodium and/or light.
The following will be considered Dose Limiting Toxicities (DLT):
- Urinary symptoms grade 3, or more over 12 weeks duration (see section 7 for toxicity grading)
- Loss of > 50% of baseline bladder volume
- Clinical decision of investigator or patient to discontinue due to toxicity.
Efficacy will be assessed on the basis of the following criteria:
- Complete Response: cystoscopy with biopsy and/or cytology without evidence of cancer.
- Partial Response: normal cystoscopy and biopsies, if obtained, but persistent positive or suspicious cytology localized to the bladder; or, for patients with CIS, > 50% reduction in extent of CIS.
- Persistent/Recurrent Disease: persistent or recurrent cancer of the same or lesser stage and grade as at enrollment without obvious increase in tumor burden.
- Progression: cancer of any greater stage or grade than at enrollment or obvious increase in tumor burden.
Referred patients will undergo post-PDT cystoscopy by the referring Urologists, who will transmit the results to the study site in Gainesville,Fl.
- Symptoms will be assessed for one month following each WBPDT by weekly telephone contact.
- Urine and blood for cytokines will be obtained before each treatment and possibly twice afterwards and stored -80oF for analysis later.
- Biopsy specimen samples from tumor and normal bladder may be obtained at cystoscopy and stored for later analysis for biomarkers.
- Patients will be followed for toxicity, disease status, urinary tract symptoms, and survival.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32608
- Malcom Randall NF/SG Veterans Administration Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pathological diagnosis of bladder cancer, non muscle invasive
- Recurrent after at least one course of standard intravesical therapy after transurethral resection (TURBT).
- Maximum debulking of tumor by TURBT/fulguration
One or more of the following:
- Contraindications to conventional intravesical therapy, including patient's refusal.
- Positive or suspicious urine cytology localized to the bladder
- Prior intravesical therapy and persistent atypia.
- Premalignant (diffuse squamous metaplasia or malakoplakia) lesions.
- Bladder capacity greater or equal to 150 cc.
- No contraindications to an appropriate anesthesia or analgesia.
- Karnofsky's performance status > 50.
- Patients must sign an informed consent form in accordance with the Institution's Review Board and FDA 21 CFR Part 50.
- Female patients must be practicing a medically acceptable form of birth control or be sterile or postmenopausal.
Exclusion Criteria:
- Pregnant or nursing mother.
- Known hypersensitivity to porphyrins.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A single arm, non-randomized Phase II Study
Non-Randomized Phase II,Single Arm Study evaluating the efficacy of whole bladder photodynamic therapy as an alternative to radical cystectomy.
|
The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dose Limiting Toxicity
Time Frame: 18 months
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease progression
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Unyime O Nseyo, M.D., NF/SGVAHS
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WBPDT-577-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Superficial Bladder Cancer
-
University of SydneyAustralian and New Zealand Urogenital and Prostate Cancer Trials Group; Cancer... and other collaboratorsCompletedSuperficial Bladder CancerUnited States, Australia, New Zealand, Canada, United Kingdom
-
University of Rome Tor VergataCompletedSuperficial Bladder CancerItaly
-
Halozyme TherapeuticsCompletedSuperficial Bladder CancerUnited States
-
Anchiano Therapeutics Israel Ltd.CompletedSuperficial Bladder CancerIsrael, United States
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompleted
-
FKD Therapies OyCompletedSuperficial Bladder Cancer
-
Abnoba GmbhCompletedSuperficial Bladder CancerEgypt, Germany
-
Mansoura UniversityCompletedCarcinoma of Urinary Bladder, SuperficialEgypt
-
National University Hospital, SingaporeNational Medical Research Council (NMRC), SingaporeCompletedCarcinoma of Urinary Bladder, SuperficialSingapore